Praxis precision medicines and ucb announce epilepsy research collaboration

Boston, dec. 13, 2022 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company, and ucb (euronext brussels: ucb), a global biopharmaceutical company, today announced a strategic collaboration, based upon praxis' prax-020 program, for the discovery of small molecule therapeutics as potential treatments of kcnt1 related epilepsies.
PRAX Ratings Summary
PRAX Quant Ranking